Vaccination prior to COVID-19 infection does not significantly affect neurological symptoms in patients with postacute sequelae of SARS-CoV-2 infection, according to a study published online Jan. 7 in Brain Communications.
Shreya Mukherjee, from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues investigated whether vaccination prior to infection alters the subsequent neurologic postacute sequelae of SARS-CoV-2 infection (neuro-PASC). The analysis included data from 200 posthospitalization neuro-PASC (PNP) and 1,100 nonhospitalized neuro-PASC (NNP) patients evaluated at a neuro COVID-19 clinic between May 2020 and January 2023.
The researchers found that among PNP patients, 87 percent had a prevaccination infection, as did 70.7 percent of NPP patients. Breakthrough infections were associated with more frequent preexisting depression/anxiety. The three most common neurological symptoms for PNP patients were brain fog (86.5 percent), numbness/tingling (56.5 percent), and headache (56.5 percent) at an average of 10 months after symptom onset. PNP breakthrough infection was more frequently associated with anosmia. For NNP patients, the most common neurological symptoms were brain fog (83.9 percent), headache (70.9 percent), and dizziness (53.8 percent). For NNP patients with prevaccination infection, anosmia (56.6 versus 39.1 percent) and dysgeusia (53.3 versus 37.3 percent) occurred more frequently than for patients with breakthrough infection, whereas those with breakthrough infection more frequently reported dizziness (61.5 versus 50.6 percent). Impaired quality of life in cognitive, fatigue, sleep, anxiety, and depression domains were seen for all PASC patients, with no differences between prevaccination infection and breakthrough infection status.
“Taken together, these results indicate that, once PNP or NNP patients develop neuro-PASC, whether they contracted SARS-CoV-2 infection prior to, or after SARS-CoV-2 vaccination makes little difference in their clinical presentation, subjective alteration of quality of life or objective cognitive dysfunction,” the authors write.
Neurological concerns regarding the COVID-19 vaccination
COVID-19 vaccination has been a critical tool in combating the pandemic, significantly reducing severe illness, hospitalization, and death. However, like any medical intervention, vaccines can have potential side effects. While most side effects are mild and temporary, there have been reports of rare neurological complications associated with COVID-19 vaccination.
Reported Neurological Complications
Some of the neurological concerns reported following COVID-19 vaccination include:
- Guillain-Barré syndrome (GBS): GBS is a rare neurological disorder in which the body’s immune system mistakenly attacks the peripheral nerves, leading to muscle weakness and paralysis. There have been reports of GBS occurring following vaccination, particularly with certain adenoviral vector vaccines. However, it’s important to note that the risk of GBS after COVID-19 infection is significantly higher than the risk after vaccination.
- Cerebral venous sinus thrombosis (CVST): CVST is a rare type of blood clot that forms in the brain’s venous sinuses.7 It has been associated with some COVID-19 vaccines, particularly those using adenoviral vector technology. However, the risk of CVST is also higher after COVID-19 infection than after vaccination.
- Transverse myelitis: Transverse myelitis is an inflammation of the spinal cord that can cause muscle weakness, sensory problems, and bladder or bowel dysfunction. There have been rare reports of transverse myelitis following COVID-19 vaccination in the Netherlands.
- Bell’s palsy: Bell’s palsy is a temporary weakness or paralysis of the facial muscles. It has been reported as a rare side effect of COVID-19 vaccination.
- Headaches and dizziness: These are common side effects of many vaccines, including COVID-19 vaccines. They are usually mild and temporary.
Understanding the Risks
It’s important to emphasize that the reported neurological complications are extremely rare. The benefits of COVID-19 vaccination in preventing severe illness and death far outweigh the risks of these rare side effects. Additionally, the risk of developing these neurological complications after COVID-19 infection is generally higher than the risk after vaccination.
Safety Monitoring and Research
Ongoing surveillance helps to identify and assess any potential risks associated with vaccines. Research is also being conducted to better understand the mechanisms behind these rare neurological complications and to develop strategies to mitigate any potential risks.
While there have been rare reports of neurological complications following COVID-19 vaccination, it’s crucial to remember that these events are extremely uncommon. The benefits of vaccination in protecting against severe COVID-19 significantly outweigh the risks of these rare side effects.